Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc (OTCQX:ANPCY) reported significant milestones in its 2022 financial results, marking a breakthrough year with FDA clearance for the Parsortix PC1 Clinical System. This system allows for the harvesting of intact cancer cells from blood samples, a first in its class. The company achieved revenue of £1.0 million in 2022, consistent with 2021, while losses rose to £21.7 million due to planned investments. An encouraging performance in Q1 2023 reported strong year-on-year revenue growth. A major partnership with Solaris Health focuses on prostate cancer, and additional contracts with pharma clients highlight increasing demand for its services. ANGLE's healthy cash position stands at £31.9 million, complemented by ongoing R&D Tax Credits, setting a solid foundation for growth.
ANGLE plc has announced a development partnership with BioView Ltd. to create a circulating tumor cell (CTC) HER2 assay for breast cancer. This collaboration utilizes ANGLE's FDA-cleared Parsortix PC1 Clinical System and BioView's microscopy technology. The first phase is projected to generate approximately £1.2 million in revenue. As breast cancer treatment evolves, there is a significant opportunity to develop a quantitative HER2 assay that can monitor patients' HER2 status over time. The HER2-low breast cancer segment, accounting for 55% of breast cancer cases, is gaining attention, especially with the introduction of targeted therapies like ENHERTU. Analysts anticipate a potential US$3 billion annual increase in sales value due to this market expansion.
ANGLE plc has presented a poster at the AACR annual meeting 2023 showcasing the capabilities of its Parsortix system to analyze circulating tumor cells (CTCs) in metastatic breast cancer (MBC) patients. The research demonstrates the successful combination of immunofluorescent (IF) staining and HER2 FISH analysis, achieving over 90% analytical sensitivity and specificity. In a study of 16 MBC patients, CTCs were identified in 81%, with 38.5% of those exhibiting high HER2 expression. The findings highlight the commercial potential for a CTC-based HER2 assay, which allows for ongoing monitoring of HER2 status, addressing an unmet medical need and potentially expanding the HER2 diagnostic market. ANGLE's innovation aligns with evolving treatment strategies for patients with varying HER2 levels.
ANGLE plc has announced a contract with Crescendo Biologics to utilize its Portrait Flex Assay in Crescendo's ongoing Phase 1 clinical trial for CB307, a drug targeting prostate cancer. The assay, developed for detecting circulating tumor cells (CTCs), boasts over 90% sensitivity and specificity, crucial for identifying druggable targets in cancer treatment. Crescendo will process patient samples using ANGLE's Parsortix system at its accredited laboratories. Both companies express enthusiasm about the collaboration, indicating potential for future partnerships. This contract highlights the growing importance of CTC biomarkers in clinical trials, giving ANGLE a stronger foothold in the immuno-oncology sector.
ANGLE plc (OTCQX:ANPCY) will release its preliminary results for the year ended 31 December 2022 on April 21, 2023. A virtual meeting for analysts is scheduled at 10:00 am BST on the same day, with registration required in advance. The company's liquid biopsy technology, notably the Parsortix system, is FDA cleared for use in metastatic breast cancer, serving as the first approved medical device to harvest intact circulating cancer cells from blood. ANGLE aims to enhance cancer diagnostics, supported by extensive clinical studies and collaborations with leading cancer centers.
ANGLE plc (OTCQX:ANPCY), a leader in liquid biopsy, announced on March 10, 2023, the approval of share options under its Remuneration Policy. The Remuneration Committee granted up to 6,000,000 LTIP options to executive directors and up to 9,000,000 Staff Share Options to employees. Following this issuance, total options outstanding will amount to 41,133,147 shares, equating to approximately 13.6% of the issued share capital. The exercise price for Staff Share Options is £0.2575. The LTIP options will vest based on performance conditions related to share price growth over three years, designed to enhance shareholder value.
ANGLE plc reported a significant change in voting rights as Global Frontier Partners, LP acquired an additional stake in the company. The acquisition increased their voting rights from 3.65% to 5.32%, totaling 13,868,946 shares. This threshold was reached on March 7, 2023, with the notification sent on March 8, 2023. Global Frontier Investments, LLC serves as the general partner for the acquired shares, impacting the control dynamics within the company. The increase in holdings signifies a noteworthy investment in ANGLE plc, which could influence future strategic decisions and shareholder value.
ANGLE plc (AIM:AGL, OTCQX:ANPCY) announced key share transactions on February 9, 2023. CEO Andrew Newland purchased 125,000 ordinary shares at 28.75 pence each, signaling confidence in the company’s prospects. Finance Director Ian Griffiths acquired 30,000 shares via his self-invested personal pension (SIPP) at 29.175 pence each. He also sold and repurchased 37,500 shares in his personal account at prices of 29.25 and 29.50 pence, respectively. These transactions were conducted on the London Stock Exchange, reflecting insider confidence amidst ongoing developments in the liquid biopsy sector.
ANGLE plc (OTCQX:ANPCY) has appointed Joseph Eid M.D. as Non-Executive Director, effective January 19, 2023. Dr. Eid, a certified oncologist with over 25 years of experience in clinical trials and drug development, previously held senior roles at major pharmaceutical firms including Merck and Bristol Myers Squibb. His significant contributions include leading the global strategy for Keytruda, enhancing the company’s focus on oncology biomarkers and clinical applications. Both Dr. Eid and the company aim to leverage his expertise to advance ANGLE’s liquid biopsy technology and commercial strategy.
ANGLE plc has reported a change in major holdings, as Aegon NV has crossed a voting rights threshold of 2.03% on January 6, 2023. This marks a decrease from a previous holding of 3.77%. Additionally, Aegon holds 0.25% voting rights through financial instruments, bringing the total to 2.28%. The notification to the Financial Conduct Authority (FCA) was completed on January 10, 2023. This change may indicate a shift in investor confidence or strategy regarding ANGLE plc's shares.